Management of bilateral malignant ovarian germ cell tumors: Experience of a single institute

Zhao,Ting; Liu,Yan; Jiang,Hongyuan; Zhang,Hao; Lu,Yuan

doi:10.3892/mco.2016.915

Management of bilateral malignant ovarian germ cell tumors: Experience of a single institute

Authors:
- Ting Zhao
- Yan Liu
- Hongyuan Jiang
- Hao Zhang
- Yuan Lu
View Affiliations

Affiliations: Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China, Department of Pathology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
Published online on: May 30, 2016 https://doi.org/10.3892/mco.2016.915
Pages: 383-387

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bilateral malignant ovarian germ cell tumors (MOGCTs) are rare. Determination of the optimal treatment modalities is crucial, as these malignancies mainly affect girls and young women who may wish to preserve their fertility. In order to review the prevalence, clinical characteristics, treatment and outcome of bilateral MOGCTs, we performed a retrospective review of patients who were diagnosed with bilateral MOGCTs and underwent primary surgery at the Obstetrics and Gynecology Hospital of Fudan University (Shanghai, China) between January, 2001 and December, 2014. Of the 130 patients investigated, 8 were diagnosed with bilateral disease, most of whom were International Federation of Gynecology and Obstetrics stage I. There was no significant difference in overall and disease‑free survival between patients with unilateral and those with bilateral disease. Cases with dysgerminoma, dysgerminoma coexisting with gonadoblastoma, yolk sac tumor and ovarian primary choriocarcinoma were included in this study. Fertility was spared in 2 patients (1 with dysgerminoma and 1 with ovarian primary choriocarcinoma). The patient with ovarian choriocarcinoma experienced relapse and was finally salvaged by radical surgery and adjuvant chemotherapy. According to our results and the published data, patients affected by bilateral MOGCTs have a satisfactory prognosis. The treatment modalities largely depend on the histological type of the tumor. Fertility‑sparing surgery may be safe for patients affected by dysgerminoma, but should be considered with caution in patients with ovarian primary choriocarcinoma.

View Figures

View References

1	Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY and Qualls CR: Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 107:1075–1085. 2006. View Article : Google Scholar : PubMed/NCBI
2	Mahdi H, Kumar S, Seward S, Semaan A, Batchu R, Lockhart D, Tamimi H and Munkarah AR: Prognostic impact of laterality in malignant ovarian germ cell tumors. Int J Gynecol Cancer. 21:257–262. 2011.PubMed/NCBI
3	Roychoudhuri R, Putcha V and Møller H: Cancer and laterality: A study of the five major paired organs (UK). Cancer Causes Control. 17:655–662. 2006. View Article : Google Scholar : PubMed/NCBI
4	Gershenson DM: Management of ovarian germ cell tumors. J Clin Oncol. 25:2938–2943. 2007. View Article : Google Scholar : PubMed/NCBI
5	Sigismondi C, Scollo P, Ferrandina G, Candiani M, Angioli R, Viganò R, Scarfone G and Mangili G: Management of bilateral malignant ovarian germ cell tumors: A MITO-9 retrospective study. Int J Gynecol Cancer. 25:203–207. 2015. View Article : Google Scholar : PubMed/NCBI
6	Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM and Whelan S: International Classification of Diseases for Oncology (ICD-O) (3rd). World Health Organization. Geneva, Switzerland: 2013.
7	Mutch DG and Prat J.: 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 133:401–404. 2014. View Article : Google Scholar : PubMed/NCBI
8	Husaini ALH, Soudy H, El Din Darwish A, Ahmed M, Eltigani A, Mubarak ALM, Sabaa AA, Edesa W, L-Tweigeri AT and Al-Badawi IA: Pure dysgerminoma of the ovary: A single institutional experience of 65 patients. Med Oncol. 29:2944–2948. 2012. View Article : Google Scholar : PubMed/NCBI
9	Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG and Wharton JT: Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol. 17:2670–2675. 1999.PubMed/NCBI
10	Dimopoulos MA, Papadopoulou M, Andreopoulou E, Papadimitriou C, Pavlidis N, Aravantinos G, Aspropotamitis A, Anagnostopoulos A, Fountzilas G, Michalas S and Pectacides D: Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: A Hellenic Cooperative Oncology Group Study. Gynecol Oncol. 70:70–74. 1998. View Article : Google Scholar : PubMed/NCBI
11	Vicus D, Beiner ME, Klachook S, Le LW, Laframboise S and Mackay H: Pure dysgerminoma of the ovary 35 years on: A single institutional experience. Gynecol Oncol. 117:23–26. 2010. View Article : Google Scholar : PubMed/NCBI
12	Lin KY, Bryant S, Miller DS, Kehoe SM, Richardson DL and Lea JS: Malignant ovarian germ cell tumor - role of surgical staging and gonadal dysgenesis. Gynecol Oncol. 134:84–89. 2014. View Article : Google Scholar : PubMed/NCBI
13	Jonson AL, Geller MA and Dickson EL: Gonadal dysgenesis and gynecologic cancer. Obstet Gynecol. 116(Suppl 2): S550–S552. 2010. View Article : Google Scholar
14	Canto P, Söderlund D, Reyes E and Méndez JP: Mutations in the desert hedgehog (DHH) gene in patients with 46,XY complete pure gonadal dysgenesis. J Clin Endocrinol Metab. 89:4480–4483. 2004. View Article : Google Scholar : PubMed/NCBI
15	Funato T, Uehara S, Takahashi M, Kozawa K, Satoh J, Sasaki T and Kaku M: Microsatellite instability in gonadal tumors of XY pure gonadal dysgenesis patients. Int J Gynecol Cancer. 12:192–197. 2002. View Article : Google Scholar : PubMed/NCBI
16	Bianco S, Agrifoglio V, Mannino F, Cefalù E and Cittadini E: Successful pregnancy in a pure gonadal dysgenesis with karyotype 46,XY patient (Swyer's syndrome) following oocyte donation and hormonal treatment. Acta Eur Fertil. 23:37–38. 1992.PubMed/NCBI
17	Cicin I, Saip P, Guney N, Eralp Y, Ayan I, Kebudi R and Topuz E: Yolk sac tumours of the ovary: Evaluation of clinicopathological features and prognostic factors. Eur J Obstet Gynecol Reprod Biol. 146:210–214. 2009. View Article : Google Scholar : PubMed/NCBI
18	Nawa A, Obata N, Kikkawa F, Kawai M, Nagasaka T, Goto S, Nishimori K and Nakashima N: Prognostic factors of patients with yolk sac tumors of the ovary. Am J Obstet Gynecol. 184:1182–1188. 2001. View Article : Google Scholar : PubMed/NCBI
19	Kurman RJ and Norris HJ: Embryonal carcinoma of the ovary: A clinicopathologic entity distinct from endodermal sinus tumor resembling embryonal carcinoma of the adult testis. Cancer. 38:2420–2433. 1976. View Article : Google Scholar : PubMed/NCBI
20	Heo EJ, Choi CH, Park JM, Lee JW, Bae DS and Kim BG: Primary ovarian choriocarcinoma mimicking ectopic pregnancy. Obstet Gynecol Sci. 57:330–333. 2014. View Article : Google Scholar : PubMed/NCBI
21	Koo HL, Choi J, Kim KR and Kim JH: Pure non-gestational choriocarcinoma of the ovary diagnosed by DNA polymorphism analysis. Pathol Int. 56:613–616. 2006. View Article : Google Scholar : PubMed/NCBI
22	Ozturk E, Ugur MG, Cebesoy FB, Aydin A, Sever T and Balat O: Good prognosis for primary ovarian pure nongestational choriocarcinoma using the EMA/CO regime. Eur J Gynaecol Oncol. 31:123–125. 2010.PubMed/NCBI
23	Wan J, Li XM and Gu J: Primary choriocarcinoma of the fallopian tube: A case report and literature review. Eur J Gynaecol Oncol. 35:604–607. 2014.
24	Beiner ME, Gotlieb WH, Korach Y, Shrim A, Stockheim D, Segal Y, Fridman E and Ben-Baruch G: Cystectomy for immature teratoma of the ovary. Gynecol Oncol. 93:381–384. 2004. View Article : Google Scholar : PubMed/NCBI